BIOADAPTIVES, INC.
For the period ended Jun 30, 2025. Filed Aug 14, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 14, 2025
BDPTStored price and day change unavailable
What changed in Management’s Discussion and Analysis?
Read the current filingPrevious report: 10-Q
Period ended 2025-03-31; filed 2025-05-13.
0001640334-25-000834
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of operationsCurrent report: 10-Q
Period ended 2025-06-30; filed 2025-08-14.
0001640334-25-001493
Item 2. Management’s Discussion and Analysis of Financial Conditionand Results of operationsThe baseline is this issuer’s latest earlier reporting period of the same form that was filed before the current report. A previous 10-Q is a different quarter, not a year-over-year comparison. Amendments are excluded.
Compared 58 previous paragraphs and 57 current paragraphs.
34 unchanged; 18 reworded; 5 added; 6 removed; 0 previous and 0 current paragraphs rearranged.
Tables are not compared: 3 previous and 3 current tables excluded. Dates, whitespace, punctuation and numbering changes are ignored; changes to financial figures remain significant.
A changed paragraph is not evidence that risk increased or decreased. An unchanged paragraph does not establish that risk stayed the same.
Added paragraphs (5)
Current report
PawPa™ Regen™ dog treats started limited sales via its website and is still going through its market testing.
Current report
Cost of Sales covers
Current report
Cash flows
Current report
Net cash used in investing activities during the six months ended June 30, 2025, was $18,000 from a purchase of property and equipment. There were no investing activities during the six months ended June 30, 2024.
Current report
Net cash provided by financing activities during the six months ended June 30, 2025, was $300,000 from issuance of Series D Preferred Stock. Net cash provided by financing activities during the six months ended June 30, 2024, was $32,096 from issuance of notes payable.
Removed paragraphs (6)
Previous report
Our animal products expected in first quarter 2025 are dog treats for anti-aging, wellness, and joint repair. These formulations are based upon extensive trials on humans, dogs, horses, hogs, and mice. The canine product are all in the form of treats making delivery and dosing very simple and effective.
Previous report
Effective February 2, 2022, the Company acquired the exclusive option to purchase U.S. Patent No. 9,783,432B (the "Patent"), covering technology used in enhancing the capability of water to hold significantly larger amounts of oxygen. The Agreement also allows the Company a two-year license to use the technology covered by the Patent, including for further development of oxygenated water products for consumers. The Agreement was more fully discussed in the Company's Form 8-K filed on February 6, 2022. As a result, The Company formed a wholly-owned subsidiary, MORO2, Inc. to study the feasibility of this technology. Unfortunately, after spending two years' effort seeking a co-packer to manufacture a test run of this product, no co-packer could be located. As a result, it declined the option to purchase this technology and returned the unit to the inventor.
Previous report
The Company signed a dealer's agreement with Pixcelcando out of Europe for their Al Body Composition Analysis technology for US distribution. It is currently carrying out free trial offers to interested parties before its major launching effort in the 2nd and 3rd quarters 2024.
Previous report
All are products are getting ready to launch in 2 nd Quarter, hence there is no revenue in this First Quarter
Previous report
There is no cost of sales this Quarter, as no product is being sold during this period
Previous report
Three Months Ended
Reworded paragraphs (18)
Previous wording
BioAdaptives' core business is to investigate, market and distribute natural plant and algal-based products and medical devices that improve health and wellness for humans and animals, with an emphasis on weight control, pain relief, anti-viral function, and anti-aging properties. BioAdaptives is reformulating its entire product line and will be bringing out new products in the first and second quarter of 2025.
Current wording
BioAdaptives’ core business is to investigate, market and distribute natural plant, and algal, - and cyanobackteria-based products and medical devices that improve health and wellness for humans and animals, with an emphasis on nootropics, anti-aging, weight control, relaxation, pain relief, and anti-viral benefits. BioAdaptives is reformulating its entire product line and started bringing out new products from the second quarter 2025.
Previous wording
Effective November 15, 2021, the Company entered into a marketing agreement for an FDA-cleared Class Tl medical device, the Lung FluteTM_ In April 2024, The Company negotiated with the sole owner of the product to assume their existing stock and their rights to all future activities on this item. It intends to actively expand its sales efforts beyond the direct sale effort of its Lung Cleanser to expand to the medical communities, pharmacies, gyms, athletic clubs, and senior communities both in US and Internationally. The Company is also exploring agreements with other medical device manufacturers; the owners of intellectual prope1ty relating to medical devices and processes; and marketing companies associated with these manufacturers and owners.
Current wording
Effective November 15, 2021, the Company entered into a marketing agreement for an FDA-cleared Class Tl medical device, the Lung Flute™. In April 2024, The Company negotiated with the sole owner of the product to assume their existing stock and their rights to all future activities on this item. It intends to actively expand its sales efforts beyond the direct sale effort of its Lung Cleanser to expand to the medical communities, pharmacies, gyms, athletic clubs, and senior communities both in US and Internationally. The Company is also exploring agreements with other medical device manufacturers; the owners of intellectual prope1ty relating to medical devices and processes; and marketing companies associated with these manufacturers and owners.
Previous wording
The Company's current products in development include dietary supplements using natural ingredients and proprietary methods of optimizing the availability of nutrients in foods and beverages. The human products are designed to aid in the control of weight. Empowering the user to lose weight while maintaining more of their lean muscle mass. The initial new product line for humans includes Zeranovia™ for healthy weight loss, Xcellera™ regenerative stem cell activator, Wynovia™ to reduce the loss of lean muscle mass while dieting.
Current wording
The Company’s current products and those in development include dietary supplements using natural ingredients and proprietary methods of optimizing the availability of nutrients in foods and beverages. The human products are designed to aid in cognitive health, regenerative stem cell activation, healthy weight loss. MyndMed™ provides Immediate cognitive enhancement (focus, clarity, motivation), medium-term resilience and memory gains, and long-term neuroprotection and cognitive health, making it a robust solution for anyone seeking to optimize mental performance and brain longevity. Xcellara™ regenerative stem cell activator, Zeranovia™ the healthy weight loss enhancer and Wynovia™ to reduce the loss of lean muscle mass while dieting.
Previous wording
In late March 2025, The Company finished the preparation to launch the Canine Product – PawPa™ Regen™, for selling from April 2025. PawPa™ is a revolutionary new pet wellness brand that leverages predictive data, artificial intelligence, and Embark Vet Services’ extensive database of over 400,000 unique DNA samples to create custom and mass-market solutions tailored to specific conditions or deficiencies as well as overall nutritional support. Backed by science and advanced technology PawPa™’s products not only enhance pet wellness but also set the new standard in pet care. “Regen” dog chew PawPa™’s flagship product is crafted with a blend of advanced nutraceutical compounds and infused with all-natural ingredients, these chews are specially formulated to enhance canine’s quality of life in their golden years. Specific benefits of the “Regen™” chew include: Regenerative Support, Energy & Vitality and Anti-aging Benefits.
Current wording
Beginning April, the Company finished the preparation to launch the Canine Product – PawPa™ Regen™. Backed by science and advanced technology PawPa™’s products not only enhance pet wellness but also set the new standard in pet care. “Regen” dog chew PawPa™’s flagship product is crafted with a blend of advanced nutraceutical compounds and infused with all-natural ingredients, these chews are specially formulated to enhance canine’s quality of life in their golden years. Specific benefits of the “Regen™” chew include: Regenerative Support, Energy & Vitality and Anti-aging Benefits.
Previous wording
The Company’s third Product ClearMynd™ MyndMed™ is finishing its pre-launch phase. MyndMed™ is designed to optimize multiple neurotransmitter systems and neuroprotective pathways, delivering broad-spectrum cognitive benefits. By synergistically targeting acetylcholine, dopamine, neuroprotection, synaptic growth, and stress reduction, MyndMed™ supports both immediate and sustained improvements in mental performance, resilience, and brain health.
Current wording
The Company’s Product MyndMed™ is finishing its pre-launch phase. MyndMed™ is designed to optimize multiple neurotransmitter systems and neuroprotective pathways, delivering broad-spectrum cognitive benefits. By synergistically targeting acetylcholine, dopamine, neuroprotection, synaptic growth, and stress reduction, MyndMed™ supports both immediate and sustained improvements in mental performance, resilience, and brain health.
Previous wording
The Company is also in the completion stage of readying its Human product Xcellara™ to launch within the next few weeks. Xcellara™ is BioAdaptives’ regenerative wellness solution, to enhance your performance, accelerate recovery, and revitalize your health. Backed by double-blind placebo-controlled clinical trials, Xcellara™ activates stem cells for cellular regeneration. Derived from a proprietary blend of nutraceutical compounds Xcellara™ is the secret weapon for success on and off the court and provides a myriad of benefits.
Current wording
Xcellara™ is BioAdaptives’ regenerative wellness solution, to enhance your performance, accelerate recovery, and revitalize your health. Backed by double-blind placebo-controlled clinical trials, Xcellara™ activates stem cells for cellular regeneration. Derived from a proprietary blend of nutraceutical compounds Xcellara™ is the secret weapon for success on and off the court and provides a myriad of benefits. In its market testing, Xcellera™ has shown it has positive effect on those being challenged with chronic fatigue.
Previous wording
Zeranovia™ is another product that is about to complete its clinical trial for launching in the second quarter. Zeranovia™ is an innovative, natural weight loss supplement designed to work exceptionally well on its own or as a complement to GLP-1 and GIP weight loss treatments such as Ozempic, Wegovy, Zepbound, and Mounjaro. It supports weight loss by dramatically suppressing appetite, enhancing insulin sensitivity, preserving muscle mass, and delivering essential nutrients. Zeranovia™ significantly enhances the effectiveness of existing treatments while providing substantial nutritional support to deter muscle wasting during a caloric deficit. Throughout the trial, extremely encouraging results are being reported of participants losing 5 to 11 pounds in a 7 to 10 day period.
Current wording
Zeranovia™ has been going through a further refining process. It is about to complete its clinical trial for launching in the last quarter. Zeranovia™ is an innovative, natural weight loss supplement designed to work exceptionally well on its own or as a complement to GLP-1 and GIP weight loss treatments such as Ozempic, Wegovy, Zepbound, and Mounjaro. It supports weight loss by dramatically suppressing appetite, enhancing insulin sensitivity, preserving muscle mass, and delivering essential nutrients. Zeranovia™ significantly enhances the effectiveness of existing treatments while providing substantial nutritional support to deter muscle wasting during a caloric deficit. Throughout the trial, extremely encouraging results are being reported of participants losing 5 to 11 pounds in a 7 to 10 day period.
Previous wording
Finally, BioAdaptives employs a dynamic affiliate marketing program, partnering with companies and individual influencers who boast large social media followings and proven success in the supplement industry. These affiliates, carefully selected for their credibility and performance, promote BioAdaptives’ products through authentic endorsements, affiliate links, and promo codes. This strategy amplifies brand visibility, drives sales, and builds trust among niche audiences, leveraging the influence of established voices in the health and wellness space to accelerate growth.
Current wording
Finally, BioAdaptives employs a dynamic affiliate marketing program, partnering with companies and individual influencers who boast large social media following and proven success in the supplement industry. These affiliates, carefully selected for their credibility and performance, promote BioAdaptives’ products through authentic endorsements, affiliate links, and promo codes. This strategy amplifies brand visibility, drives sales, and builds trust among niche audiences, leveraging the influence of established voices in the health and wellness space to accelerate growth.
Previous wording
All of the Company's nutraceutical products are considered dietary supplements or natural foods, and we carefully avoid making health, drug, or disease cure claims that could trigger regulatory compliance issues and affect our ability to market BioAdaptives products. Our active ingredients are all plant, fungi, or algal-based and sourced worldwide from reputable suppliers who employ stringent compliance and sustainable agriculture practices.
Current wording
All of the Company’s nutraceutical products are considered dietary supplements or natural foods, and we carefully avoid making health, drug, or disease cure claims that could trigger regulatory compliance issues and affect our ability to market BioAdaptives products. Our active ingredients are all plant, fungi, algal, or cyanobacteria-based and sourced worldwide from reputable suppliers who employ stringent compliance and sustainable agriculture practices.
Previous wording
BioAdaptives actively investigates new products, techniques, and novel applications of existing products or technology in our research. The Company's research has focused on investigating all-natural supplement formulations that activate primitive cells, including stem cells and their derivatives, and natural ingredients that encourage stem cell proliferation. In 2022, the Company started a product line utilizing algae and mushrooms.
Current wording
BioAdaptives actively investigates new products, techniques, and novel applications of existing products or technology in our research. The Company’s research has focused on investigating all-natural supplement formulations that activate primitive cells, including stem cells and their derivatives, and natural ingredients that encourage stem cell proliferation. In 2022, the Company started a product line utilizing cyanobacteria and mushrooms.
Previous wording
Liquidity -- Financial Performance – Three Months Ended March 31, 2025, and 2024
Current wording
Liquidity -- Financial Performance – Three Months Ended June 30 th. 2025, and 2024
Previous wording
We had a net loss of $197,176 for the three-month period ended March 31 2025, which was $109,571 less than the net loss of $306,707 for the three-month period ended March 31, 2024. The change in our results is mainly due to the Change in operating expenses of fair value of derivative liabilities
Current wording
We had a net loss of $157,914 for the three-month period ended June 30, 2025, which was $25,103 less than the net loss of $183,017for the three-month period ended June 30, 2024. The change in our results is mainly due to the Change in operating expenses. Of fair value of derivative liabilities
Previous wording
The Company recorded interest expenses of $9,647 and $ 54,615 for the three months ended March 31,, 2025, and 2024. It also show a change in fair value of derivative liabilities of $61,659 and (202,260) for March 31, 2025 and 2024.
Current wording
The Company recorded interest expenses of $9,649 and $ 17,969 for the three months ended June 30, 2025, and 2024. It also shows a change in fair value of derivative liabilities of $130,954 and (77.020) for June 30, 2025, and 2024.
Previous wording
As a result of our operating expenses the Company reported a net loss of $ 197,136 and $ 306,707 for the three months ended March 31, 2025, and 2024.
Current wording
As a result of our operating expenses the Company reported a net loss of $ 157,914 and $ 183,017 for the three months ended June 30, 2025, and 2024.
Previous wording
Our balance sheet as of March 31 2025, reflects current assets of $110,448 , including cash in the amount of $39,564 .
Current wording
Our balance sheet as of June 30, 2025, reflects current assets of $255,515, including cash in the amount of $210,582
Previous wording
Net cash provided (used) by operating activities during the three months ended March 31, 2025, was $97,906 an increase of $56,725 from net cash used of $41,181 in operating activities during the three months ended March 31, 2024.
Current wording
Net cash used in operating activities during the six months ended June 30, 2025, was $208,888, an increase of $116,251 from net cash used of $92,637 in operating activities during the six months ended June 30, 2024.
Previous wording
As of March 31, 2025, we have insufficient cash to operate our business at the current level for the next twelve months and insufficient cash to achieve our business goals. The success of our business plan beyond the next 12 months is contingent upon us obtaining additional financing. We intend to fund operations through debt and/or equity financing arrangements, as well as the sales of our various new product lines, which may be insufficient to fund our capital expenditures, working capital, or other cash requirements. We do not have any formal commitments or arrangements for the sales of stock or the advancement or loan of funds at this time. There can be no assurance that such additional financing will be available to us on acceptable terms, or at all.
Current wording
As of June 30, 2025, we have insufficient cash to operate our business at the current level for the next twelve months and insufficient cash to achieve our business goals. The success of our business plan beyond the next 12 months is contingent upon us obtaining additional financing. We intend to fund operations through debt and/or equity financing arrangements, as well as the sales of our various new product lines, which may be insufficient to fund our capital expenditure, working capital, or other cash requirements. We do not have any formal commitments or arrangements for the sales of stock or the advancement or loan of funds at this time. There can be no assurance that such additional financing will be available to us on acceptable terms, or at all.
Previous wording
On March 31, 2025, we had $39,564 of cash on-hand and an accumulated deficit of $9,360,442, and as noted throughout this report and our financial statements and notes thereto, our independent auditors expressed their substantial doubt as to our ability to continue as a going concern as of December 31, 2025. We anticipate to be incurring some losses in the near future, until all the products are launch and have maximized their sales. Our ability to continue as a going concern is dependent upon our ability to successfully compete, operate profitably and/or raise additional capital through other means.
Current wording
On June 30, 2025, we had $210,582 of cash on-hand and an accumulated deficit of $9,518,365, and as noted throughout this report and our financial statements and notes thereto, our independent auditors expressed their substantial doubt as to our ability to continue as a going concern as of December 31, 2025. We anticipate to be incurring some losses in the near future, until all the products are launch and have maximized their sales. Our ability to continue as a going concern is dependent upon our ability to successfully compete, operate profitably and/or raise additional capital through other means.